•Variations of maternal care are linked with differentiated gene expression in OB.•The OB of HL mothers expressed more Drd1a, Prlr, Htr1a, Htr1b and Esr1 than LL.•No difference of gene expression was ...found in the HP, PFC or ST of mothers LL or HL.•There were differences of gene expression in the HP between lactating and virgins.•LL showed a decrease in the frequency of nursing and remained longer off the pups.
For most mammalian species, maternal behavior has an essential role in the development of the offspring. The frequency of licking/grooming (LG) the pups has been used as a parameter to evaluate maternal care, having mothers with high (HL) or low (LL) frequencies of LG. This study aimed to analyze the gene expression of the receptors for dopamine (Drd1a), prolactin (Prlr), serotonin (Htr1a, Htr1b), estrogen (Esr1, Esr2), and of Bdnf in the olfactory bulb (OB), hippocampus (HP), prefrontal cortex (PFC), and striatum (ST) of Wistar rats from three groups: LL (n=8); HL (n=8); virgin females in diestrus (D; n=6). Maternal behavior was studied between the 1st and 7th postpartum days. Brain parts were analyzed by qRT-PCR. LL showed a decrease in the frequency of nursing, and an increase of remaining off the pups. There was an increase in gene expression of Drd1a, Prlr, Htr1a, Htr1b and Esr1 in the OB of HL, compared to LL. In the HP, Drd1a, Prlr and Htr1a were differently expressed when comparing HL, or LL, with D. The main finding is that HL had higher gene expression levels in the OB, which is a crucial structure to promote behavioral differences.
Brain-derived neurotrophic factor (BDNF) and its receptor, tropomyosin-related receptor kinase B (TrkB) are involved in the maturation of B lymphocytes in the bone marrow (BM), promote cell ...differentiation in B-cell malignancies, and are associated with poor prognosis in adults with acute leukemia (AL). However, the role of BDNF in pediatric AL remains poorly understood.
We carried out a cohort observational study to evaluate BDNF levels in BM or peripheral blood (PB) samples from children with AL.
BM or PB samples were collected from 57 children and adolescents with acute lymphoid leukemia (ALL), 14 children and adolescents with acute myeloid leukemia (AML), and 44 healthy individuals (HI) of the same age range.
BDNF levels at diagnosis in AL patients were significantly lower when compared to HI. Samples from patients in complete remission from disease had higher levels of BDNF compared to those obtained from patients with malignant cells. Moreover, BDNF levels at diagnosis in patients who died were significantly lower compared to those found in survivors.
These findings provide the first evidence for a possible role of BDNF as a marker of active disease and poor prognosis in pediatric AL.
As leucemias correspondem a 30% dos tumores pediátricos, e constituem as neoplasias mais frequentes em indivíduos com menos de 15 anos. Apesar da elevada taxa de cura, frequentemente a ela está ...associada resistência à quimioterapia e efeitos colaterais tardios. Por isso, novas estratégias de tratamento, diagnóstico e prognóstico são necessárias. O fator neurotrófico derivado do cérebro (BDNF) e seus receptores de quinase relacionados à tropomiosina (tropomyosin related kinase, ou Trk) estão envolvidos com muitos processos na medula óssea (MO). Entretanto, o papel do BDNF em leucemias agudas (LA) pediátricas ainda não é bem conhecido. O objetivo desse estudo foi analisar os níveis de BDNF em amostras de MO ou sangue periférico (SP) de crianças com LA, e iniciar a caracterização dos efeitos de agonistas e antagonistas de neurotrofinas sobre culturas primárias de leucemias linfóides agudas em diferentes momentos terapêuticos Foram coletadas amostras de MO ou SP de crianças e adolescentes com leucemia linfóide aguda (LLA), crianças e adolescentes com leucemia mielóide aguda (LMA), e indivíduos saudáveis (IS) da mesma faixa etária. Para análise dos níveis séricos de BDNF utilizou-se kit de imuno-ensaio enzimático tipo sanduíche. Quando comparados aos IS os níveis de BDNF de pacientes com LA, ao diagnóstico, foram significativamente menores. Resultados similares foram observados nos pacientes durante indução, consolidação, diagnóstico e tratamento de recidiva. Da mesma forma, os níveis de BDNF foram inferiores em pacientes que receberam transfusão de plaquetas e, ao diagnóstico naqueles pacientes que foram a óbito. Para a caracterização dos efeitos de agonistas e antagonistas de neurotrofinas em cultura de células, amostras de pacientes ao momento do diagnóstico e no momento de indução do tratamento foram utilizadas. Os linfócitos foram extraídos e, após plaqueamento, as células foram tratadas com BDNF (Sigma, B3795), NGF (Sigma, SRP3015) e K252a (Sigma, 05288) por 72 horas. A viabilidade foi avaliada pelo método de exclusão por azul de Tripan. Devido às dificuldades no cultivo das células, esses dados ainda estão em análise.
Leukemias account for 30% of pediatric tumors and are the most frequent cancers in people under 15 years. Despite the high cure rate, often it is associated with resistance to chemotherapy and late side effects. Therefore, new strategies for treatment, diagnosis and prognosis are necessary. The brain-derived neurotrophic factor (BDNF) and their kinase receptor related tropomyosin (tropomyosin related kinase, and Trk) are involved in many processes in bone marrow (BM), however, the role of BDNF in acute leukemias (AL) pediatric it is not well known. The aim of this study was to analyze the BDNF levels in BM samples or peripheral blood (PB) of children with AL, and start the characterization of the effects of agonists and antagonists on neurotrophin primary cultures of acute lymphoblastic leukemias in different therapeutic moments. BM or PB samples were collected from children and adolescents with acute lymphoblastic leukemia (ALL), children and adolescents with acute myeloid leukemia (AML), and healthy individuals (HI) of the same age. For analysis of serum levels of BDNF was used sandwich enzyme immunoassay kit. When compared to HI, BDNF levels in patients with AL at diagnosis were significantly lower. Similar results were observed in patients during induction, consolidation, diagnosis and treatment of relapse. Similarly, BDNF levels were lower in patients receiving platelet transfusion and at diagnosis in patients that died. To characterize the effects of agonists and antagonists for neurotrophin in cell culture, samples of patients at diagnosis and at the time of induction treatment were used. Lymphocytes were extracted and, after plating, cells were treated with BDNF (Sigma B3795), NGF (Sigma, SRP3015) and K252a (Sigma, 05288) for 72 hours. Viability was assessed by exclusion of trypan blue method. Due to difficulties in cell culture, these data are still under analysis.
